Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
2025.11.18 22:24

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares rose 6.76% to $12.01 on Tuesday, despite a general market downturn. The NASDAQ fell 1.21% and the Dow Jones dropped 1.07%. This marks the second consecutive day of gains for Corbus, though it remains 41.59% below its 52-week high. Compared to competitors, Vanda Pharmaceuticals rose 21.59%, Fortress Biotech increased 2.30%, and Viking Therapeutics fell 1.20%. Trading volume was higher than the 50-day average.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rallied 6.76% to $12.01 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.21% to 22,432.85 and Dow Jones Industrial Average falling 1.07% to 46,091.74. This was the stock's second consecutive day of gains. Corbus Pharmaceuticals Holdings Inc. closed 41.59% short of its 52-week high of $20.56, which the company achieved on October 20th. The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 21.59% to $5.35, Fortress Biotech Inc. (FBIO) rose 2.30% to $2.67, and Viking Therapeutics Inc. (VKTX) fell 1.20% to $37.76. Trading volume (465,848) eclipsed its 50-day average volume of 389,522. Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-18-25 1724ET
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.